Sunday, April 20, 2008

Xanthus' Symadex Reverses Disease in Preclinical Mouse Models of multiple sclerosis.

Xanthus' Symadex Reverses Disease in Preclinical Mouse Models of ...
PR-Inside.com (Pressemitteilung) - Wien,Austria
Given the compound's safety profile and oral availability, Xanthus believes Symadex represents an exciting drug opportunity. Xanthus Pharmaceuticals ...
See all stories on this topic

Xanthus' Symadex Reverses Disease in Preclinical Mouse Models of ...
Genetic Engineering News (press release) - New Rochelle,NY,USA
Xanthus Pharmaceuticals, Inc. presented data demonstrating that Symadex(TM), a selective FLT3 inhibitor, acted to reverse disease in mouse models of both ...
See all stories on this topic

Xanthus' Symadex Reverses Disease In Preclinical Mouse Models Of Multiple Sclerosis
Xanthus Pharmaceuticals, Inc. presented data demonstrating that SymadexTM, a selective FLT3 inhibitor, acted to reverse disease in mouse models of both acute and chronic multiple sclerosis. Biomarkers of macrophage and dendritic cells showed a significant correction back towards the baseline levels found in healthy control animals

Alzheimer's Starts Earlier For Heavy Drinkers, Smokers
Heavy drinkers and heavy smokers develop Alzheimer's disease years earlier than people with Alzheimer's who do not drink or smoke heavily, according to research that will be presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12-19, 2008.

Affiris Develops Alzheimer's Vaccine
The Viennese biotech company Affiris is taking stock of the progress achieved to date in its clinical Alzheimer's vaccination programme. All the Alzheimer's patients treated so far as part of the toxicological trials have tolerated the treatment extremely well.


Critical Detail Of Cellular Defense Against Genetic Mistakes Discovered By Researchers
Researchers are closing in on a completed diagram of how human cells protect themselves against constant genetic mistakes that contribute to most diseases, according to a study to be published in the April 18 edition of the journal Cell.

Help arrives for prescription medications
Idaho Mountain Express and Guide - Ketchum,ID,USA
Nationally syndicated talk show host Montel Williams, who was diagnosed with multiple sclerosis in 1999, is the national spokesman for the PPA. ...
See all stories on this topic

Walk to help cast public eye on MS
Roanoke Times - Roanoke,VA,USA
B-list celebrities such as Annette Funicello and Montel Williams have MS. But they don't attract the public awareness or sympathy that Michael J. Fox does ...
See all stories on this topic


Homer City woman takes positive approach to MS fight
Blairsville Dispatch - PA, USA
Aside from relapsing/remitting and secondary progressive MS, there are two other forms--primary progressive and progressive/relapsing. ...
See all stories on this topic

Drug Fails to Slow Nerve Damage
New York Times - United States
Rituxan failed to reach its main goal of slowing disability for people with primary progressive multiple sclerosis after almost two years of treatment, ...
See all stories on this topic

AAN: Monoclonal Antibodies Shine in Relapsing-Remitting MS but Not ...
MedPage Today - Little Falls,NJ,USA
Dr. Jung agreed that neither of the more serious adverse events were a deal breaker for the drug, because both can be monitored unlike the progressive ...
See all stories on this topic

Penwest Pharmaceuticals Co. Q4 2007 Earnings Call Transcript
Seeking Alpha - New York,NY,USA
These defects are strongly associated with several orphan progressive neurodegenerative disorders that are both chronic and serious in nature. ...
See all stories on this topic

MS ‘Wonder’ Drug: Hopes dashed as trials discover it’s no better ...
What Doctors Don't Tell You - London,UK
A two-year study has discovered that it is no better than placebo in slowing disability among sufferers with primary progressive MS. ...
See all stories on this topic

Genentech, Biogen Idec's Rituxan Misses Lofty Mark in MS Trial.
Therapeutics Daily (subscription) (press release) - Newtown,PA,USA
... to show that the drug slowed disease progression in patients with a hard-to-treat form of MS known as primary-progressive multiple sclerosis, or PPMS. ...
See all stories on this topic

Ahead of the Bell: Rituxan Trial Failure
Houston Chronicle - United States
Late Monday, Genentech and Biogen reported that Rituxan did not reach its main goal of slowing disease progression for patients with primary-progressive ...
See all stories on this topic


Biogen, Elan See Rise in Tysabri Use
TheStreet.com - USA
Biogen Idec BIIB and Elan ELN presented positive safety data and new patient rates for multiple sclerosis drug Tysabri, at the annual meeting of the ...
See all stories on this topic

Shares in Elan soar on MS drug safety data
Irish Independent - Dublin,Ireland
The stock was upgraded to "buy" from "neutral" by Goldman Sachs on prospects for its multiple sclerosis drug Tysabri, which is co-developed with partner ...
See all stories on this topic

Elan says data supports plasma exchange as tool to accelerate ...
Forbes - NY,USA
Plc. and Biogen Idec Inc. said the PLEX study has shown that plasma exchange accelerates the removal of TYSABRI (natalizumab) from blood serum in patients ...
See all stories on this topic

Elan Inc. Stock Tanks After Alzheimer’s Trial Ends
Newsinferno.com - New York,NY,USA
Tysabri had actually been removed from the market in 2005 because several patients taking it had died from a neurological disorder called progressive ...
See all stories on this topic


FTY720, a novel oral therapy in development for MS, shows ...
PR Newswire (press release) - New York,NY,USA
... NJ, April 15 /PRNewswire-FirstCall/ -- The investigational oral therapy FTY720 (fingolimod) continues to demonstrate sustained benefits in patients with ...
See all stories on this topic

FTY720, a Novel Oral Therapy in Development for MS, Shows ...
PharmaLive.com (press release) - Newtown,PA,USA
EAST HANOVER, NJ, April 15, 2008 /PRNewswire-FirstCall/ -- The investigational oral therapy FTY720 (fingolimod) continues to demonstrate sustained benefits ...
See all stories on this topic

Oral Drug Delays MS Relapse
MedHeadlines - Chicago,IL,USA
The research team, led by Giancarlo Comi, MD, of Milan’s Vita-Salute San Raffaele University, used an oral medication, FTY720 (fingolimod) for six months to ...
See all stories on this topic

Euroshares open up on Wall St, Asian gains; L'Oreal falls on Q1 ...
Interactive Investor - London,England,UK
Novartis moved 0.98 percent higher as it said Tuesday Phase II studies of its investigational oral therapy FTY720 has demonstrated sustained benefits in ...
See all stories on this topic

Novartis says MS drug FTY720 shows sustained benefits in long-term ...
CNNMoney.com - USA
Results showed that 73 percent of patients who began the study on FTY720 5 mg remained free from relapses after three years, as did 68 percent of those who ...
See all stories on this topic

Pill Reduces Relapses in MS Patients
drkoop.com - USA
In the study, Comi's team treated 281 people with relapsing MS with FTY720 (fingolimod) or a placebo. After six months, two-thirds of the patients who ...
See all stories on this topic

Oral drug, FTY720, reduces disease activity in Multiple Sclerosis
EurekAlert (press release) - Washington,DC,USA
The results reported are from an extension of a six-month study with 281 people with relapsing MS, two-thirds of whom took the drug FTY720 (fingolimod) and ...
See all stories on this topic


PreCISe study shows Teva's copaxone reduces risk of developing CDMS
PharmaBiz Fri, 18 Apr 2008 9:38 PM PDT
Teva Pharmaceutical Industries Ltd. posted new results from the PreCISe study, which demonstrated that early treatment with Copaxone (glatiramer acetate injection) significantly reduced the risk of developing clinically definite multiple sclerosis (CDMS) by 45 per cent compared to placebo.
Successful Patient Advocacy Work In Slovakia - "The Association Of Young People With MS" In Slovakia Makes Changes ...
Medical News Today Sat, 19 Apr 2008 3:13 AM PDT
Together with Dr Lubica Prochazkova - chief doctor of Neurological section for Multiple Sclerosis in Slovakia and involded in the Association - they succeeded in cancelling the age restriction of 45 which prevented MS patients to access DMDs in Slovakia. There is no age restriction any more in Slovakia for having Interferons being prescribed.
Oral Drug Reduces Disease Activity In Multiple Sclerosis, Study Suggests
Science Daily Fri, 18 Apr 2008 11:38 PM PDT
A drug that can be taken orally reduces the number of attacks people with multiple sclerosis have, according to new research. After six months, those taking FTY720 had more than 50 percent fewer relapses, or attacks, than those who took the placebo.

Scientists reprogram mature B cells to embryonic-stem-cell-like state
Thaindian.com - Bangkok,Bangkok,Thailand
... B cells may enable them to create mouse models that will aid in understanding autoimmune diseases, including multiple sclerosis and type 1 diabetes. ...
See all stories on this topic

Fully Differentiated Cells Can Be Reprogrammed To Induced Pluripotent Stem Cells
Fully mature, differentiated B cells can be reprogrammed to an embryonic-stem-cell-like state, without the use of an egg according to a study published in the April 18 issue of Cell.In previous research, induced pluripotent stem (IPS) cells have been created from fibroblasts, a specific type of skin cells that may differentiate into other types of skin cells.

New European Multiple Sclerosis Platform Project: Roundtable For National Endorsement Of The EMSP "Code" And Consensus Papers
Since 2003 - year of the EP resolution - EMSP (European Multiple Scleroris Platform) has been pursuing an important advocacy work focused on health inequalities in the European Union and beyond.

Human Interest_Features
Tampabay.com - St. Petersburg,FL,USA
One of the few hopeful avenues of ALS research has involved the transplanting of embryonic stem cells. Such research has been limited for seven years in the ...
See all stories on this topic


Prescription help bus visits
Moberly Monitor Index - Moberly,MO,USA
Television talk show host Montel Williams is PPA's national spokesman. 'Montel has multiple sclerosis,' said Lopes. 'Who better would understand ...
See all stories on this topic


0 Comments:

Post a Comment

Links to this post:

Create a Link

<< Home